Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Preferred Stock Liabilities (2019 - 2020)

Pliant Therapeutics (PLRX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $100.0 million as the latest value for Q1 2020.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $100.0 million in Q1 2020 year-over-year; TTM through Mar 2020 was $100.0 million, a N/A change, with the full-year FY2019 number at $62.5 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $100.0 million for Q1 2020 at Pliant Therapeutics, up from $62.5 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $100.0 million in Q1 2020 to a low of $62.5 million in Q4 2019.